SeqOnce Biosciences

SeqOnce Biosciences

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.2M

Overview

Bandit Bio (operating under the SeqOnce brand) is a private, commercial-stage company providing research-use molecular biology tools, including multiplex qPCR kits and RhinoSeq NGS library prep kits. Founded as a spin-out from the University of Southern California, the company leverages expertise in molecular biology and technology development to deliver rapid, informative nucleic acid testing solutions. It operates as a portfolio company of G3 Genomics and targets researchers in genomics and pathogen detection with its streamlined protocols and multi-platform support. The company is revenue-generating, selling its kits and providing technical support to the global research community.

Genetics & Genomics

Technology Platform

Focus on rapid multiplex qPCR assays and simplified NGS library prep kits designed for use on open-source, third-party laboratory instruments. The platform emphasizes workflow speed, higher throughput, and broad instrument compatibility.

Funding History

1
Total raised:$3.2M
Seed$3.2M

Opportunities

The growing demand for rapid, multiplexed pathogen detection in research and applied markets presents a significant opportunity.
Furthermore, the trend towards workflow simplification in next-generation sequencing creates a strong market for its effective and easy-to-use RhinoSeq library prep kits.

Risk Factors

The company faces intense competition from large, established life science tools corporations.
Its technology, based on reagent formulations, may also face challenges related to intellectual property protection and the risk of being reverse-engineered by competitors.

Competitive Landscape

Bandit Bio competes in the crowded life science research tools market against giants like Thermo Fisher, Qiagen, and Bio-Rad in qPCR, and Illumina and others in NGS library prep. Its differentiation lies in its focus on rapid, simple, open-platform solutions, carving out a niche among cost-conscious researchers seeking high-performance alternatives to vendor-locked systems.